Onderzoeker
Jens Tijtgat
- Trefwoorden:Geneeskunde
- Disciplines:Natuurwetenschappen, Sociale wetenschappen
Affiliaties
- Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Medische Oncologie (Departement)
Lid
Vanaf1 aug 2020 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf6 jul 2020 → Heden - Faculteit Economische en Sociale Wetenschappen en Solvay Business School (Faculteit)
Lid
Vanaf2 jul 2022 → 18 nov 2022 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 aug 2020 → 14 jan 2024 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 aug 2020 → 20 okt 2022 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf6 jul 2020 → 17 jan 2024 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf28 jul 2017 → 25 jun 2020
Publicaties
1 - 10 van 13
- Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma(2024)
Auteurs: Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, et al.
- 1136P Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases(2023)
Auteurs: Iris Dirven, An-Sofie Vander Mijnsbrugge, Jens Tijtgat, Manon Vounckx, B Neyns
Pagina's: 681-681 - Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia(2023)
Auteurs: Iris Dirven, An-Sofie Vander Mijnsbrugge, Sacha Mignon, Jens Tijtgat, Nicolas Kint, B Neyns
Pagina's: 338-344 - Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series(2023)
Auteurs: Jens Tijtgat, Evan Maarten Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, A Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, et al.
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Auteurs: Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pagina's: 1-13 - A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, B Neyns
Pagina's: 183-191 - Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Auteurs: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, Gil Awada, Valerie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Auteurs: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L Aerts, B Neyns, Sandra Tuyaerts
- Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Auteurs: Jens Tijtgat, Julia Katharina Schwarze, Gil Awada, B Neyns, Sandrine Aspeslagh
Pagina's: 272-276 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, B Neyns